According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “
Shares of Nantkwest stock traded down $0.06 on Thursday, hitting $1.05. 4,042 shares of the company were exchanged, compared to its average volume of 317,484. The stock has a market cap of $110.51 million, a P/E ratio of -0.87 and a beta of 2.60. Nantkwest has a 1-year low of $0.93 and a 1-year high of $4.23. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.09 and a quick ratio of 4.09.
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.